{"entity":{"id":"chum","kind":"institution","name":"Centre hospitalier de l'Université de Montréal (CHUM)","aka":["CHUM","CRCHUM"],"tldr":"The CHUM is the Université de Montréal's adult teaching hospital; Bertrand Routy's 2018 work here showed that gut bacteria shape response to checkpoint inhibitors, Fred Saad co-led prostate cancer trials such as PROpel, and it runs Quebec's largest oncology trial programme.","summary":"The CHUM is the Université de Montréal's adult teaching hospital, consolidated on a new downtown campus in 2017, with the Centre de recherche du CHUM (CRCHUM) and the Institut du cancer de Montréal as its research arms. Bertrand Routy's 2018 Science paper showed that antibiotics blunt checkpoint inhibitor efficacy and that specific gut bacteria predict response, launching faecal microbiota transplant trials to overcome immunotherapy resistance. Urologist Fred Saad has led or co-led landmark prostate cancer trials, including PROpel (olaparib plus abiraterone), and Réjean Lapointe's group develops TIL and T-cell therapies. The hospital runs Quebec's largest oncology clinical trial programme in French and English.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Centre_hospitalier_de_l'Universit%C3%A9_de_Montr%C3%A9al","links":[{"label":"CHUM","url":"https://www.chumontreal.qc.ca"},{"label":"CRCHUM (archived copy)","url":"https://web.archive.org/web/20180506044652/http://crchum.chumontreal.qc.ca/"}],"tags":[],"related":[],"cancers":["prostate","melanoma","ovarian","nsclc"],"sections":[],"technologies":["microbiome-modulation-io","til-therapy","checkpoint-inhibitor"],"targets":[],"drugs":["olaparib","abiraterone"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["marie-eve-desrosiers"],"bottlenecks":["b-immunotherapy-response"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Montréal, QC","country":"CA","lat":45.511,"lng":-73.557,"institutionType":"hospital","website":"https://www.chumontreal.qc.ca","university":"Université de Montréal","programs":["Microbiome and immunotherapy","Prostate cancer trials","T-cell immunotherapy","Ovarian cancer biobanking"]},"route":"/institutions/chum/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"microbiome-modulation-io","kind":"technology","name":"Microbiome modulation to unlock immunotherapy","route":"/technologies/microbiome-modulation-io/"},{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"person":[{"id":"fred-saad","kind":"person","name":"Fred Saad","route":"/people/fred-saad/"},{"id":"marie-eve-desrosiers","kind":"person","name":"Marie-Eve Desrosiers","route":"/people/marie-eve-desrosiers/"}],"bottleneck":[{"id":"b-immunotherapy-response","kind":"bottleneck","name":"No one can predict who responds to immunotherapy","route":"/bottlenecks/b-immunotherapy-response/"}],"institution":[{"id":"chu-de-quebec","kind":"institution","name":"CHU de Québec - Université Laval","route":"/institutions/chu-de-quebec/"},{"id":"ciusss-emtl-maisonneuve-rosemont","kind":"institution","name":"Hôpital Maisonneuve-Rosemont / CIUSSS de l'Est-de-l'Île-de-Montréal","route":"/institutions/ciusss-emtl-maisonneuve-rosemont/"}]}}